Bolt Biotherapeutics, Inc. (BOLT) Financial Statements (2025 and earlier)

Company Profile

Business Address 900 CHESAPEAKE DRIVE
REDWOOD CITY, CA 94063
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:128,600192,800186,219
Cash and cash equivalent10,8109,24427,383
Short-term investments91,379159,644158,836
Other undisclosed cash, cash equivalents, and short-term investments26,41123,912 
Restricted cash and investments 1,7651,5651,565
Prepaid expense   
Other undisclosed current assets(24,657)(21,619)1,376
Total current assets:105,708172,746189,160
Noncurrent Assets
Operating lease, right-of-use asset19,12022,07224,445
Property, plant and equipment4,9576,4536,158
Long-term investments and receivables26,41323,94385,348
Long-term investments26,41323,94385,348
Restricted cash and investments1,7651,5651,565
Other noncurrent assets1,8211,0281,042
Total noncurrent assets:54,07655,061118,558
TOTAL ASSETS:159,784227,807307,718
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,3819,3619,658
Employee-related liabilities4,886
Accounts payable2,9873,5943,574
Accrued liabilities6,3945,7671,198
Deferred revenue2,2011,9932,869
Other undisclosed current liabilities8,87411,7648,801
Total current liabilities:20,45623,11821,328
Noncurrent Liabilities
Long-term debt and lease obligation:   21,854
Liabilities, other than long-term debt26,58733,18314,417
Deferred revenue9,10712,92114,207
Other liabilities 4342210
Operating lease, liability17,43720,22021,854
Total noncurrent liabilities:26,58733,18336,271
Total liabilities:47,04356,30157,599
Equity
Equity, attributable to parent112,741171,506250,119
Common stock 1  
Additional paid in capital476,988467,513457,430
Accumulated other comprehensive income (loss)37(919)(321)
Accumulated deficit(364,285)(295,088)(206,990)
Total equity:112,741171,506250,119
TOTAL LIABILITIES AND EQUITY:159,784227,807307,718

Income Statement (P&L) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues7,8765,7291,260
Sublease income5401,2391,451
Other income   
Gross profit:7,8765,7291,260
Operating expenses(84,072)(96,050)(94,048)
Operating loss:(76,196)(90,321)(92,788)
Nonoperating income (expense)6,9992,223(5,803)
Investment income, nonoperating6,9992,223281
Loss from continuing operations:(69,197)(88,098)(98,591)
Loss before gain (loss) on sale of properties:(98,591)
Net loss available to common stockholders, diluted:(69,197)(88,098)(98,591)

Comprehensive Income ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(69,197)(88,098)(98,591)
Comprehensive loss:(69,197)(88,098)(98,591)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent956(598)(321)
Comprehensive loss, net of tax, attributable to parent:(68,241)(88,696)(98,912)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: